search icon
ensc-img

Ensysce Biosciences Inc, Common Stock

ENSC

NAQ

$6.75

-$0.42

(-5.86%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.81M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
52.04K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.12 L
$30.9 H
$6.75

About Ensysce Biosciences Inc, Common Stock

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameENSCSectorS&P500
1-Week Return-17.68%0.31%-1.26%
1-Month Return5.3%0.6%-4.16%
3-Month Return164.71%-9.44%-0.46%
6-Month Return-2.49%-5.15%3.58%
1-Year Return-60.18%0.33%22.47%
3-Year Return-99.94%4.53%25.13%
5-Year Return-99.98%35.98%77.7%
10-Year Return-99.98%100.72%190.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.76M3.93M3.53M2.52M2.23M[{"date":"2019-12-31","value":44.87,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.82,"profit":true},{"date":"2022-12-31","value":64.19,"profit":true},{"date":"2023-12-31","value":56.74,"profit":true}]
Cost of Revenue3.33M1.37M151.0019.84M7.59M[{"date":"2019-12-31","value":16.78,"profit":true},{"date":"2020-12-31","value":6.9,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.25,"profit":true}]
Gross Profit(3.33M)2.56M3.53M(17.31M)(5.36M)[{"date":"2019-12-31","value":-94.27,"profit":false},{"date":"2020-12-31","value":72.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-490.29,"profit":false},{"date":"2023-12-31","value":-151.71,"profit":false}]
Gross Margin(188.70%)65.18%100.00%(686.08%)(240.17%)[{"date":"2019-12-31","value":-188.71,"profit":false},{"date":"2020-12-31","value":65.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-686.11,"profit":false},{"date":"2023-12-31","value":-240.18,"profit":false}]
Operating Expenses3.33M1.61M19.87M24.22M5.36M[{"date":"2019-12-31","value":13.74,"profit":true},{"date":"2020-12-31","value":6.66,"profit":true},{"date":"2021-12-31","value":82.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.13,"profit":true}]
Operating Income(3.33M)(1.61M)(19.87M)(24.22M)(10.72M)[{"date":"2019-12-31","value":-332867400,"profit":false},{"date":"2020-12-31","value":-161328700,"profit":false},{"date":"2021-12-31","value":-1987043100,"profit":false},{"date":"2022-12-31","value":-2422209500,"profit":false},{"date":"2023-12-31","value":-1071818700,"profit":false}]
Total Non-Operating Income/Expense-456.92K(14.36M)(4.97M)11.88K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3142.01,"profit":false},{"date":"2022-12-31","value":-1087.78,"profit":false},{"date":"2023-12-31","value":2.6,"profit":true}]
Pre-Tax Income921.15K(160.88K)(29.15M)(24.21M)(10.63M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-17.46,"profit":false},{"date":"2021-12-31","value":-3164.06,"profit":false},{"date":"2022-12-31","value":-2627.97,"profit":false},{"date":"2023-12-31","value":-1153.58,"profit":false}]
Income Taxes(555.20K)777.85K(151.00)753.88K(264.00)[{"date":"2019-12-31","value":-71.38,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-0.02,"profit":false},{"date":"2022-12-31","value":96.92,"profit":true},{"date":"2023-12-31","value":-0.03,"profit":false}]
Income After Taxes-(938.73K)(29.15M)(24.96M)(10.63M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-93872600,"profit":false},{"date":"2021-12-31","value":-2914575000,"profit":false},{"date":"2022-12-31","value":-2496156100,"profit":false},{"date":"2023-12-31","value":-1062601100,"profit":false}]
Income From Continuous Operations365.95K4.31M(29.15M)(24.21M)(12.60M)[{"date":"2019-12-31","value":8.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-676.12,"profit":false},{"date":"2022-12-31","value":-561.56,"profit":false},{"date":"2023-12-31","value":-292.29,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income1.48M(938.73K)(29.15M)(24.96M)(10.61M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-63.58,"profit":false},{"date":"2021-12-31","value":-1974.17,"profit":false},{"date":"2022-12-31","value":-1690.76,"profit":false},{"date":"2023-12-31","value":-718.87,"profit":false}]
EPS (Diluted)242.800.67(9.52)(24.98)(5.30)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.28,"profit":true},{"date":"2021-12-31","value":-3.92,"profit":false},{"date":"2022-12-31","value":-10.29,"profit":false},{"date":"2023-12-31","value":-2.18,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ENSC
Cash Ratio 1.48
Current Ratio 3.24

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ENSC
ROA (LTM) -131.94%
ROE (LTM) -427.89%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ENSC
Debt Ratio Lower is generally better. Negative is bad. 0.30
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ENSC
Trailing PE NM
Forward PE NM
P/S (TTM) 6.13
P/B 1.35
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Ensysce Biosciences Inc share price today?

Ensysce Biosciences Inc (ENSC) share price today is $6.75

Can Indians buy Ensysce Biosciences Inc shares?

Yes, Indians can buy shares of Ensysce Biosciences Inc (ENSC) on Vested. To buy Ensysce Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENSC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ensysce Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Ensysce Biosciences Inc (ENSC) via the Vested app. You can start investing in Ensysce Biosciences Inc (ENSC) with a minimum investment of $1.

How to invest in Ensysce Biosciences Inc shares from India?

You can invest in shares of Ensysce Biosciences Inc (ENSC) via Vested in three simple steps:

  • Click on Sign Up or Invest in ENSC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ensysce Biosciences Inc shares
What is Ensysce Biosciences Inc 52-week high and low stock price?

The 52-week high price of Ensysce Biosciences Inc (ENSC) is $30.9. The 52-week low price of Ensysce Biosciences Inc (ENSC) is $2.12.

What is Ensysce Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Ensysce Biosciences Inc (ENSC) is

What is Ensysce Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ensysce Biosciences Inc (ENSC) is 1.35

What is Ensysce Biosciences Inc dividend yield?

The dividend yield of Ensysce Biosciences Inc (ENSC) is 0.00%

What is the Market Cap of Ensysce Biosciences Inc?

The market capitalization of Ensysce Biosciences Inc (ENSC) is $8.81M

What is Ensysce Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Ensysce Biosciences Inc is ENSC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top